The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NVCR | -15.61% | -89.51% | -36.26% | -30% |
| S&P | +19.89% | +109.18% | +15.89% | +251% |
Novocure's tumor-treating field devices use electric fields to disrupt the replication of cancer cells.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $167.20M | 7.8% |
| Gross Profit | $122.48M | 2.3% |
| Gross Margin | 73.25% | -3.9% |
| Market Cap | $1.44B | -14.6% |
| Market Cap / Employee | $0.97M | 0.0% |
| Employees | 1.5K | 2.4% |
| Net Income | -$37.27M | -21.9% |
| EBITDA | -$32.36M | -9.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $344.64M | 82.2% |
| Accounts Receivable | $85.23M | 27.1% |
| Inventory | 39.1 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $237.32M | 100.6% |
| Short Term Debt | $560.62M | 0.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -13.75% | -1.1% |
| Return On Invested Capital | -13.94% | -6.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $14.92M | 4959.6% |
| Operating Free Cash Flow | $20.57M | 98.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 8.93 | 5.37 | 5.48 | 4.13 | -11.43% |
| Price to Sales | 2.93 | 5.34 | 3.16 | 3.15 | -6.05% |
| Price to Tangible Book Value | 8.93 | 5.37 | 5.48 | 4.13 | -11.43% |
| Enterprise Value to EBITDA | -23.70 | -85.52 | -47.97 | -54.77 | 3.69% |
| Return on Equity | -46.7% | -45.5% | -48.1% | -50.6% | 27.45% |
| Total Debt | $683.34M | $696.73M | $700.25M | $797.94M | 18.10% |
The cancer-focused medical-device maker received the go-ahead to enter a brand-new market. Here's why the news should make investors giddy.
Medical devices can be ultra reliable, lucrative business, but there are plenty of ways for companies to blow it, too.
Recurring revenue, monopolistic market positions, and returns that tend to beat even the risky biotechs tie these three together.
NVCR earnings call for the period ending December 31, 2024.
NVCR earnings call for the period ending September 30, 2024.
NVCR earnings call for the period ending June 30, 2024.
NVCR earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
